1. Home
  2. NAAS vs CELU Comparison

NAAS vs CELU Comparison

Compare NAAS & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NaaS Technology Inc.

NAAS

NaaS Technology Inc.

HOLD

Current Price

$3.23

Market Cap

35.8M

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

N/A

Current Price

$1.35

Market Cap

34.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NAAS
CELU
Founded
2019
2016
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.8M
34.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
NAAS
CELU
Price
$3.23
$1.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
23.5K
71.7K
Earning Date
03-31-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$21,817,052.00
$40,578,000.00
Revenue This Year
$378.49
N/A
Revenue Next Year
N/A
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.96
$1.00
52 Week High
$40.32
$4.35

Technical Indicators

Market Signals
Indicator
NAAS
CELU
Relative Strength Index (RSI) 44.56 46.91
Support Level $3.01 $1.25
Resistance Level $3.30 $1.33
Average True Range (ATR) 0.19 0.10
MACD 0.01 0.03
Stochastic Oscillator 50.43 94.31

Price Performance

Historical Comparison
NAAS
CELU

About NAAS NaaS Technology Inc.

Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: